Hilsenbeck SG - Search Results

1

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.

Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R. Veeraraghavan J, et al. Among authors: hilsenbeck sg. NPJ Breast Cancer. 2021 May 27;7(1):63. doi: 10.1038/s41523-021-00274-0. NPJ Breast Cancer. 2021. PMID: 34045483 Free PMC article.

2

Prognostic factors: rationale and methods of analysis and integration.

Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Clark GM, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1994;32(1):105-12. doi: 10.1007/BF00666211. Breast Cancer Res Treat. 1994. PMID: 7819579 Review.

3

Heat shock proteins and drug resistance.

Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CK. Fuqua SA, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1994;32(1):67-71. doi: 10.1007/BF00666207. Breast Cancer Res Treat. 1994. PMID: 7819588 Review.

4

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N. Grøndahl-Hansen J, et al. Among authors: hilsenbeck sg. Breast Cancer Res Treat. 1997 Apr;43(2):153-63. doi: 10.1023/a:1005744914124. Breast Cancer Res Treat. 1997. PMID: 9131271

5

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

6

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

7

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Hilsenbeck SG, et al. Breast Cancer Res Treat. 1998;52(1-3):227-37. doi: 10.1023/a:1006133418245. Breast Cancer Res Treat. 1998. PMID: 10066085

8

Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.

O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC. O'Connell P, et al. J Natl Cancer Inst. 1999 Aug 18;91(16):1391-7. doi: 10.1093/jnci/91.16.1391. J Natl Cancer Inst. 1999. PMID: 10451444

9

Significance of axillary lymph node metastasis in primary breast cancer.

Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Jatoi I, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1999 Aug;17(8):2334-40. doi: 10.1200/JCO.1999.17.8.2334. J Clin Oncol. 1999. PMID: 10561295

10

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

365 results

Search Page